|
Dynavax
Technologies (DVAX)
Website:
www.dynavax.com
Press Release:
Dynavax's
HEPLISAV(TM) Hepatitis B Vaccine Shows Statistically Significant Results in
Phase 3 Trial
Announced statistically
significant results from the primary endpoint analysis of a Phase 3 trial
comparing HEPLISAV, its hepatitis B virus (HBV) vaccine, to GlaxoSmithKline's
Engerix-B vaccine in a difficult-to-immunize population of older adults.
The data show that after three
doses, HEPLISAV provided seroprotection to 100% of subjects versus 73.1% for
Engerix-B.
To view the Full Press Release
please visit http://biz.yahoo.com/prnews/061128/sftu131.html?.v=50
To see the full profile for
Dynavax Technologies, click
here.
For the latest Quote and News on DVAX
Click
Here.
To get up to Date on the latest Small-Cap
News visit www.smallcapreview.com
Approximate Financials
as of November 28, 2006
Market Cap:
37.9 Million
Outstanding Shares:
160 Million
52 Low / High: $8.20
/ $3.62
Price: $7.40
Overview
Dynavax Technologies Corporation discovers,
develops, and intends to commercialize innovative TLR9 agonist-based products to
treat and prevent allergies, infectious diseases, cancer, and chronic
inflammatory diseases using versatile, proprietary approaches that alter immune
system responses in highly specific ways. The Company's agonists are based on
immunostimulatory sequences, or ISS, which are short DNA sequences that enhance
the ability of the immune system to fight disease and control chronic
inflammation.
Dynavax’s pipeline includes: TOLAMBA(TM), a
ragweed allergy immunotherapeutic, for which a major safety and efficacy trial (DARTT)
is currently underway, and that is in a supportive clinical trial in ragweed
allergic children; HEPLISAV(TM), a hepatitis B vaccine in Phase 3; and a therapy
for non-Hodgkins lymphoma in Phase 2. Its preclinical asthma and COPD programs
are partnered with AstraZeneca. Funding for the company’s other preclinical
programs in cancer, hepatitis B and hepatitis C therapies, and for an influenza
vaccine has been provided by Symphony Dynamo, Inc. and NIH, and these programs
represent future partnering opportunities.
DVAX
Investor Highlights
- Announced statistically
significant results from the primary endpoint analysis of a Phase 3 trial
comparing HEPLISAV, its hepatitis B virus (HBV) vaccine, to
GlaxoSmithKline's Engerix-B vaccine in a difficult-to-immunize population of
older adults.
- Reported data from a Phase 2b
study showing TOLAMBA(TM), the company's novel ragweed investigational
therapy, benefited treated patients, regardless of the severity of their
disease.
- Presented preclinical data
that shows its influenza (flu) vaccine can improve the immunogenicity of
standard flu vaccines. Dynavax said that the data from mouse and primate
models demonstrate that co-administration of Dynavax's flu vaccine with
standard vaccine enhances the immune response of the standard vaccine,
allows reduction of standard vaccine dosage, and provides extra layers of
protection that are not strain-dependent.
Recent
News and Press Releases
Dynavax's
HEPLISAV(TM) Hepatitis B Vaccine Shows Statistically Significant Results in
Phase 3 Trial
Dynavax
Reports New TOLAMBA Data at ACAAI Meeting
Dynavax
Technologies Names Michael Ostrach VP, Chief Business Officer and General
Counsel
Dynavax
Announces Third Quarter 2006 Financial Results and Updates 2006 Financial
Guidance
Dynavax's
Universal Flu Vaccine Improves Response of Standard Flu Vaccines
SmallCapReview.com
feature stock reports are intended to be stock ideas, NOT recommendations.
Please do your own research before investing. It is crucial that you at least
look at current SEC filings and read the latest press releases. For
continuing coverage of DVAX, please sign up for our free newsletter. Information
contained in this report was extracted from current documents filed with the
SEC, the company web site and other publicly available sources deemed reliable.
For more information see our disclaimer section, a link of which can be found on
our web site. This document contains forward-looking statements, particularly as
related to the business plans of the Company, within the meaning of Section 27A
of the Securities Act of 1933 and Sections 21E of the Securities Exchange Act of
1934, and are subject to the safe harbor created by these sections. Actual
results may differ materially from the Company's expectations and estimates. The
information provided in this report is not intended for distribution to, or use
by, any person or entity in any jurisdiction or country where such distribution
or use would be contrary to law or regulation or which would subject us to any
registration requirement within such jurisdiction or country.
Copyright
SmallCapReview.com. All rights reserved. SmallCapReview.com is not a Registered
Broker/Dealer or Financial Advisor, nor do we hold ourselves out to be. All
materials presented on our web site and individual reports released to the
public through this web site, e-mail or any other means of transmission are not
to be regarded as investment advice and are only for informative purposes.
Before making a purchase or sale of any securities featured on our web site
or mentioned in our reports, we strongly encourage and recommend consultation
with a registered securities representative. This is not to be construed as
a solicitation or recommendation to buy or sell securities. As with any stock,
companies we select to profile involve a degree of investment risk and
volatility. Particularly Small-Caps and OTC-BB stocks. All investors are
cautioned that they may lose all or a portion of their investment if they decide
to make a purchase in any of our profiled companies. Past performance of our
profiled stocks is not indicative of future results. The accuracy or
completeness of the information on our web site or within our reports is only as
reliable as the sources they were obtained from. The profile and opinions
expressed herein are expressed as of the date the profile is posted on site and
are subject to change without notice. No investor should assume that reliance on
the views, opinions or recommendations contained herein will produce profitable
results. SmallCapReview.com may hold
positions in securities mentioned herein, and may make purchases or sales in
such securities featured on our web site or within our reports. In order to be
in full compliance with the Securities Act of 1933, Section 17(b),
SmallCapReview.com will disclose in it's disclaimer, what, if any compensation
was received for our efforts in researching, presenting and disseminating
this information to our subscriber database and featuring the report on the
SmallCapReview.com web site. SmallCapReview.com
has not been compensated for its efforts in presenting the Dynavax Technologies
profile on its website and distributing it to its database of subscribers. SmallCapReview.com
may decide to purchase or sell shares on a voluntary basis in the open market
before, during or after the profiling period of this report. Information
presented on our web site and within our reports contain "forward looking
statements" within the meaning of Section 27A of the Securities Act of 1933
and Section 21E
of the Securities Exchange Act of 1934. Any statements that express or involve
discussions with respect to predictions, expectations, beliefs, plans,
projections, objectives, goals, assumptions or future events or performance
are not statements of historical fact and may be "forward looking
statements." Forward looking statements are based on expectations,
estimates and projections at the time the statements are made that involve a
number of risks and uncertainties which could cause actual results or events to
differ materially from those presently anticipated. Forward looking statements
in this action may be identified through the use of words such as
“expects’”, “will,” “anticipates,” “estimates, “believes,”
or that by statements indicating certain actions “may,” “could,” or
“might” occur.
THE
READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN
ANY SECURITIES MENTIONED. INVESTING IN SMALL CAP SECURITIES IS SPECULATIVE AND
CARRIES A HIGH DEGREE OF RISK.
We
encourage our readers to invest carefully and read the investor information
available at the web sites of the Securities and Exchange Commission (SEC) at: http://www.sec.gov
and/or the National Association of Securities Dealers (NASD) at: http://www.nasd.com
. Readers can review all public filings by companies at the SEC's EDGAR
page. The NASD has published information on how to invest carefully at its web
site.
|